SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Propanc Health Group Corp (OTCMKTS:PPCH), a growing healthcare company with the prime focus on the development of treatments for cancer patients, has announced the appointment of Maxim Group LLC as its strategic advisor.

Maxim is one of the leading names in the field of investment management, securities, and investment banking. As per the reports, it will provide investment banking services and strategic corporate planning services to Propanc Health Group Corp. The primary objective of Maxim Group as the strategic advisor to Propanc Health Group will be to assist the company in maximizing the shareholders’ value through various investment banking services.

Management Call:

The senior management teams of both the companies are delighted to have entered into this strategic alliance. According to James Nathanielsz, Chief Executive Officer, Propanc Health, it’s great to have entered into strategic alliance with a leading investment banking firm like Maxim Group. Propanc Health has certain plans with regard to company’s growth in the coming months, and partnering with Maxim will ensure that those plans are executed without any hassle. It’s going to be fun to work with the entire team of Maxim Group.

The management team of Maxim is equally delighted to have got the chance to work with Propanc Health Group. While talking to reporters, company’s Head of the Capital Growth Advisory Group, Karl Brenza, stated that it’s delightful to have a partner like Propanc Health Group Corp (OTCMKTS:PPCH). The company looks forward to helping Propanc Group in creating value for its shareholders through investment banking capacities.

Maxim Group is a perfect combination of experienced management executives with great skills, which makes it a suitable choice for this role. Maxim Group’s growth prospects and strong IP portfolio have given it an edge over others who’re in this race. It looks forward to contributing to Propanc’s growth in every possible aspect.